Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Family Medicine · BURTON, MI · NPI 1962794628
Verified facts
CMS Open Payments records show Nilufa Akhter, M.D. received $17.14 in general payments during 2025 across 1 reported records.
Exact Sciences Corporation accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.14 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $17.14 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 627 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 306 | 94 |
| Lisinopril | Lisinopril | 283 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 247 | 85 |
| Metformin Hcl | Metformin Hcl | 242 | 66 |
| Losartan Potassium | Losartan Potassium | 231 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 179 | 58 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 174 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 164 | 45 |
| Omeprazole | Omeprazole | 153 | 48 |
| Ozempic | Semaglutide | 147 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 40 |
| Furosemide | Furosemide | 127 | 48 |
| Potassium Chloride | Potassium Chloride | 124 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 63 |
| Trazodone Hcl | Trazodone Hcl | 108 | 34 |
| Famotidine | Famotidine | 106 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 27 |
| Meloxicam | Meloxicam | 98 | 41 |
| Novolog Flexpen | Insulin Aspart | 91 | 24 |
| Farxiga | Dapagliflozin Propanediol | 90 | 25 |
| Carvedilol | Carvedilol | 83 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 32 |
| Gabapentin | Gabapentin | 81 | 32 |
| Sertraline Hcl | Sertraline Hcl | 79 | 23 |
| Allopurinol | Allopurinol | 78 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 27 |
| Jardiance | Empagliflozin | 75 | 20 |
| Eliquis | Apixaban | 72 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 38 |
| Montelukast Sodium | Montelukast Sodium | 65 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 22 |
| Symbicort | Budesonide/Formoterol Fumarate | 57 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 20 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 52 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 19 |
| Prednisone | Prednisone | 51 | 41 |
| Buspirone Hcl | Buspirone Hcl | 48 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 17 |
| Simvastatin | Simvastatin | 47 | 13 |
| Spironolactone | Spironolactone | 46 | 13 |
| Ibuprofen | Ibuprofen | 45 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Januvia | Sitagliptin Phosphate | 43 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 17 |
| Risedronate Sodium | Risedronate Sodium | 43 | 15 |
| Trulicity | Dulaglutide | 42 | 11 |
| Bumetanide | Bumetanide | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | 13 |
| Naproxen | Naproxen | 33 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 12 |
| Bupropion Xl | Bupropion Hcl | 29 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 28 | 11 |
| Atenolol | Atenolol | 27 | 11 |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | 11 |
| Azithromycin | Azithromycin | 24 | 18 |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 11 |
| Sucralfate | Sucralfate | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 18 |
| Pregabalin | Pregabalin | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 18 |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $17.14 · 1 records | Exact Sciences Corporation | Cologuard Collection Kit | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error